Ziaee Amir, Oveisi Sonia, Abedini Atefeh, Hashemipour Sima, Karimzadeh Toktam, Ghorbani Azam
Department of Endocrinology, Metabolic Disease Research Center, Qazvin University of Medical Science, Qazvin, Iran.
Acta Med Indones. 2012 Jan;44(1):16-22.
to compare the effectiveness of metformin and pioglitazone in ameliorating insulin resistance and cardiovascular risk factors in women with polycystic ovary syndrome (PCOS).
this study was a randomized clinical trial to compare treatment with metformin and pioglitozone. Fifty two women with PCOS aged 20-45 years were randomly allocated to one of the two treatment groups. All patients underwent clinical and biochemical evaluation and analyses involving these measures which consisted of repeated measures MANOVA using the pre- and post-intervention fasting blood sugar (FBS), lipid profiles, body mass index (BMI), serum insulin in two groups.
weight and BMI were significantly decreased in metformin group but not in case of pioglitazone. FBS, serum triglycerides, total cholesterol were all reduced significantly by both metfomin and pioglitazone. Insulin resistance measured by homeostasis model assessment (HOMA) method was significantly decreased in both treatment groups (P<0.05). There were no significant differences between treatments in most of variables except BMI.
these results suggest pioglitazone is as effective as metformin in improving insulin sensitivity and some cardiovascular risk biomarkers but it has no significant effect on reducing BMI and body weight.
比较二甲双胍和吡格列酮改善多囊卵巢综合征（PCOS）女性胰岛素抵抗和心血管危险因素的有效性。
本研究是一项比较二甲双胍和吡格列酮治疗效果的随机临床试验。52例年龄在20 - 45岁的PCOS女性被随机分配到两个治疗组之一。所有患者均接受了临床和生化评估及分析，这些措施包括使用干预前后空腹血糖（FBS）、血脂谱、体重指数（BMI）、两组血清胰岛素进行重复测量多元方差分析。
二甲双胍组体重和BMI显著降低，而吡格列酮组则不然。二甲双胍和吡格列酮均显著降低了FBS、血清甘油三酯和总胆固醇。通过稳态模型评估（HOMA）方法测量的胰岛素抵抗在两个治疗组中均显著降低（P<0.05）。除BMI外，大多数变量在治疗之间没有显著差异。
这些结果表明，吡格列酮在改善胰岛素敏感性和一些心血管风险生物标志物方面与二甲双胍一样有效，但对降低BMI和体重没有显著影响。
